[S02DA03, antipyrine, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Antipyrine.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Sulindac is combined with Lisdexamfetamine.]
[N05AL01, sulpiride, Sulpiride may decrease the stimulatory activities of Lisdexamfetamine.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Azapropazone.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Mercaptopurine.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Lisdexamfetamine.]
[R03CC03, terbutaline, The risk or severity of hypertension can be increased when Terbutaline is combined with Lisdexamfetamine.]
[N07XX06, tetrabenazine, The metabolism of Tetrabenazine can be decreased when combined with Lisdexamfetamine.]
[N05AE05, lurasidone, The therapeutic efficacy of Lurasidone can be decreased when used in combination with Lisdexamfetamine.]
[A04AD10, dronabinol, The metabolism of Lisdexamfetamine can be decreased when combined with Dronabinol.]
[N04BC07, apomorphine, The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Lisdexamfetamine.]
[R03DA07, theobromine, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Theobromine.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Lisdexamfetamine.]
[R06AD03, thiethylperazine, Thiethylperazine may decrease the stimulatory activities of Lisdexamfetamine.]
[N05AB08, thioproperazine, The therapeutic efficacy of Thioproperazine can be decreased when used in combination with Lisdexamfetamine.]
[N05AC02, thioridazine, The therapeutic efficacy of Thioridazine can be decreased when used in combination with Lisdexamfetamine.]
[N05AF04, thiothixene, Thiothixene may decrease the stimulatory activities of Lisdexamfetamine.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Lisdexamfetamine.]
[G04BE06, moxisylyte, The therapeutic efficacy of Moxisylyte can be decreased when used in combination with Lisdexamfetamine.]
[V04CJ01, thyrotropin, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Thyrotropin.]
[V04CJ02, thyrotropin-releasing hormone, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Protirelin.]
[N05AL03, tiapride, Tiapride may decrease the stimulatory activities of Lisdexamfetamine.]
[B01AC05, ticlopidine, The metabolism of Lisdexamfetamine can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, Lisdexamfetamine may increase the analgesic activities of Tilidine.]
[S01ED01, timolol, The metabolism of Timolol can be decreased when combined with Lisdexamfetamine.]
[M02AX02, tolazoline, The therapeutic efficacy of Tolazoline can be decreased when used in combination with Lisdexamfetamine.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Tolmetin is combined with Lisdexamfetamine.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Lisdexamfetamine is combined with Tramadol.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the hypertensive activities of Lisdexamfetamine.]
[N06AX05, trazodone, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Lisdexamfetamine.]
[C03AA06, trichlormethiazide, Lisdexamfetamine may decrease the antihypertensive activities of Trichlormethiazide.]
[A03AB12, mepenzolate, The risk or severity of Tachycardia can be increased when Lisdexamfetamine is combined with Mepenzolate.]
[N05AB06, trifluoperazine, The therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Lisdexamfetamine.]
[N05AD02, trifluperidol, Trifluperidol may decrease the stimulatory activities of Lisdexamfetamine.]
[N05AA05, triflupromazine, Triflupromazine may decrease the stimulatory activities of Lisdexamfetamine.]
[N04AA01, trihexyphenidyl, The risk or severity of Tachycardia can be increased when Trihexyphenidyl is combined with Lisdexamfetamine.]
[A03AA05, trimebutine, The risk or severity of Tachycardia can be increased when Lisdexamfetamine is combined with Trimebutine.]
[R06AD01, trimeprazine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Alimemazine.]
[C02BA01, trimethaphan, Lisdexamfetamine may decrease the antihypertensive activities of Trimethaphan.]
[N06AA06, trimipramine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Trimipramine.]
[R06AC04, tripelennamine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Tripelennamine.]
[R06AX07, triprolidine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Triprolidine.]
[A03BB01, butylscopolamine, The risk or severity of Tachycardia can be increased when Lisdexamfetamine is combined with Butylscopolamine.]
[N06AX24, vilazodone, The metabolism of Lisdexamfetamine can be decreased when combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of serotonin syndrome can be increased when Tryptophan is combined with Lisdexamfetamine.]
[C09CA09, azilsartan medoxomil, Lisdexamfetamine may decrease the antihypertensive activities of Azilsartan medoxomil.]
[L02BX03, abiraterone, The metabolism of Lisdexamfetamine can be decreased when combined with Abiraterone.]
[J05AG05, rilpivirine, The metabolism of Lisdexamfetamine can be decreased when combined with Rilpivirine.]
[R03AC18, indacaterol, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Indacaterol.]
[C08DA01, verapamil, The therapeutic efficacy of Verapamil can be decreased when used in combination with Lisdexamfetamine.]
[N06AX09, viloxazine, The metabolism of Lisdexamfetamine can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Lisdexamfetamine can be decreased when combined with Vinblastine.]
[C04AX07, vincamine, Lisdexamfetamine may decrease the antihypertensive activities of Vincamine.]
[S01AA13, fusidic acid, The metabolism of Lisdexamfetamine can be decreased when combined with Fusidic acid.]
[N01AX15, xenon, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Xenon.]
[C03BA10, xipamide, Lisdexamfetamine may decrease the antihypertensive activities of Xipamide.]
[N05AF05, zuclopenthixol, Lisdexamfetamine may decrease the sedative and stimulatory activities of Zuclopenthixol.]
[L01EC01, vemurafenib, The metabolism of Lisdexamfetamine can be decreased when combined with Vemurafenib.]
[S01XA15, ascorbic acid, The serum concentration of Lisdexamfetamine can be decreased when it is combined with Ascorbic acid.]
[N05AE04, ziprasidone, Lisdexamfetamine may decrease the sedative and stimulatory activities of Ziprasidone.]
[N02BA01, aspirin, The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Lisdexamfetamine.]
[G04BD07, tolterodine, The metabolism of Tolterodine can be decreased when combined with Lisdexamfetamine.]
[C07AB03, atenolol, The therapeutic efficacy of Atenolol can be decreased when used in combination with Lisdexamfetamine.]
[S01FA01, atropine, The risk or severity of hypertension can be increased when Atropine is combined with Lisdexamfetamine.]
[A08AA11, lorcaserin, The metabolism of Lisdexamfetamine can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Lisdexamfetamine can be increased when it is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Lisdexamfetamine can be decreased when combined with Cobicistat.]
[A02AA05, magnesium silicate, The serum concentration of Lisdexamfetamine can be increased when it is combined with Magnesium silicate.]
[C01CA18, octopamine, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Octopamine.]
[A02AC02, calcium silicate, The serum concentration of Lisdexamfetamine can be increased when it is combined with Calcium silicate.]
[N04BD02, rasagiline, Rasagiline may increase the hypertensive activities of Lisdexamfetamine.]
[C08CA13, lercanidipine, Lisdexamfetamine may decrease the antihypertensive activities of Lercanidipine.]
[A03FA09, mosapride, The risk or severity of serotonin syndrome can be increased when Lisdexamfetamine is combined with Mosapride.]
[N06DA02, donepezil, The metabolism of Donepezil can be decreased when combined with Lisdexamfetamine.]
[N02CC03, zolmitriptan, The risk or severity of serotonin syndrome can be increased when Zolmitriptan is combined with Lisdexamfetamine.]
[R06AC06, thonzylamine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Thonzylamine.]
[G04BD10, darifenacin, The metabolism of Lisdexamfetamine can be decreased when combined with Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Diethyl ether.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be decreased when combined with Lisdexamfetamine.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Lisdexamfetamine.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be decreased when combined with Lisdexamfetamine.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Lisdexamfetamine can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, Lisdexamfetamine may decrease the antihypertensive activities of Bendroflumethiazide.]
[G03XC05, ospemifene, The metabolism of Lisdexamfetamine can be decreased when combined with Ospemifene.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Benorilate.]
[N05AD07, benperidol, Benperidol may decrease the stimulatory activities of Lisdexamfetamine.]
[A06AX06, tegaserod, The metabolism of Lisdexamfetamine can be decreased when combined with Tegaserod.]
[H03AA04, tiratricol, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Tiratricol.]
[R02AD01, benzocaine, The metabolism of Benzocaine can be decreased when combined with Lisdexamfetamine.]
[M01AH01, celecoxib, The metabolism of Lisdexamfetamine can be decreased when combined with Celecoxib.]
[N02CC02, naratriptan, The risk or severity of serotonin syndrome can be increased when Naratriptan is combined with Lisdexamfetamine.]
[L04AA18, everolimus, The metabolism of Lisdexamfetamine can be decreased when combined with Everolimus.]
[N04AC01, benztropine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Benzatropine.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Benzydamine.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Lisdexamfetamine.]
[H05AA03, parathyroid hormone, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Parathyroid hormone.]
[N06AX28, levomilnacipran, The risk or severity of serotonin syndrome can be increased when Lisdexamfetamine is combined with Levomilnacipran.]
[C08EA02, bepridil, The metabolism of Lisdexamfetamine can be decreased when combined with Bepridil.]
[C02KX05, riociguat, Lisdexamfetamine may decrease the antihypertensive activities of Riociguat.]
[C02KX04, macitentan, Lisdexamfetamine may decrease the antihypertensive activities of Macitentan.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Lisdexamfetamine.]
[N06AX26, vortioxetine, The risk or severity of serotonin syndrome can be increased when Lisdexamfetamine is combined with Vortioxetine.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Lisdexamfetamine.]
[C01CA27, droxidopa, The therapeutic efficacy of Lisdexamfetamine can be increased when used in combination with Droxidopa.]
[C07AB04, acebutolol, The therapeutic efficacy of Acebutolol can be decreased when used in combination with Lisdexamfetamine.]
[L04AA32, apremilast, The metabolism of Lisdexamfetamine can be increased when combined with Apremilast.]
[N07CA01, betahistine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Betahistine.]
[S01ED02, betaxolol, The therapeutic efficacy of Betaxolol can be decreased when used in combination with Lisdexamfetamine.]
[C02CC01, bethanidine, Lisdexamfetamine may decrease the antihypertensive activities of Bethanidine.]
[L04AC11, siltuximab, The metabolism of Lisdexamfetamine can be increased when combined with Siltuximab.]
[A03BA03, hyoscyamine, The risk or severity of Tachycardia can be increased when Hyoscyamine is combined with Lisdexamfetamine.]
[R03AC19, olodaterol, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Olodaterol.]
[D11AA01, glycopyrronium, The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Lisdexamfetamine.]
[A16AX10, eliglustat, The metabolism of Lisdexamfetamine can be decreased when combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Lisdexamfetamine can be decreased when combined with Oritavancin.]
[N05AA04, acepromazine, The therapeutic efficacy of Acepromazine can be decreased when used in combination with Lisdexamfetamine.]
[A06AH03, naloxegol, Lisdexamfetamine may increase the analgesic activities of Naloxegol.]
[N04AA02, biperiden, The metabolism of Lisdexamfetamine can be decreased when combined with Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Lisdexamfetamine.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Lisdexamfetamine.]
[N06AX11, mirtazapine, Lisdexamfetamine may increase the serotonergic activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Lisdexamfetamine can be increased when combined with Secukinumab.]
[L01XH03, panobinostat, The metabolism of Lisdexamfetamine can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be decreased when combined with Lisdexamfetamine.]
[A03AA09, difemerine, The risk or severity of Tachycardia can be increased when Lisdexamfetamine is combined with Difemerine.]
[J05AP06, asunaprevir, The metabolism of Lisdexamfetamine can be decreased when combined with Asunaprevir.]
[A07DA06, eluxadoline, Lisdexamfetamine may increase the analgesic activities of Eluxadoline.]
[N05AX16, brexpiprazole, The therapeutic efficacy of Brexpiprazole can be decreased when used in combination with Lisdexamfetamine.]
[A04AD14, rolapitant, The metabolism of Lisdexamfetamine can be decreased when combined with Rolapitant.]
[G02CX02, flibanserin, The risk or severity of serotonin syndrome can be increased when Lisdexamfetamine is combined with Flibanserin.]
[A06AD03, magnesium peroxide, The serum concentration of Lisdexamfetamine can be increased when it is combined with Magnesium peroxide.]
[N05AX15, cariprazine, Cariprazine may decrease the stimulatory activities of Lisdexamfetamine.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Acemetacin.]
[S01EC01, acetazolamide, Acetazolamide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.]
[N05AB07, acetophenazine, Acetophenazine may decrease the stimulatory activities of Lisdexamfetamine.]
[A02BC03, lansoprazole, The metabolism of Lisdexamfetamine can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Lisdexamfetamine.]
[J02AC05, isavuconazole, The metabolism of Lisdexamfetamine can be decreased when combined with Isavuconazole.]
[B01AC27, selexipag, Lisdexamfetamine may decrease the antihypertensive activities of Selexipag.]
[G04CA01, alfuzosin, The therapeutic efficacy of Alfuzosin can be decreased when used in combination with Lisdexamfetamine.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Alminoprofen.]
[A02AB06, aloglutamol, The serum concentration of Lisdexamfetamine can be increased when it is combined with Aloglutamol.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Lisdexamfetamine.]
[A02AD05, aluminum magnesium silicate, The serum concentration of Lisdexamfetamine can be increased when it is combined with Almasilate.]
[A02AB03, aluminum phosphate, The serum concentration of Lisdexamfetamine can be increased when it is combined with Aluminium phosphate.]
[R06AB01, brompheniramine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Dexbrompheniramine.]
[N06AA19, amineptin, The therapeutic efficacy of Amineptine can be increased when used in combination with Lisdexamfetamine.]
[C08CA01, amlodipine, Lisdexamfetamine may decrease the antihypertensive activities of Amlodipine.]
[N01BB01, bupivacaine, The metabolism of Bupivacaine can be decreased when combined with Lisdexamfetamine.]
[C07AA19, bupranolol, The therapeutic efficacy of Bupranolol can be decreased when used in combination with Lisdexamfetamine.]
[N07BC01, buprenorphine, Lisdexamfetamine may increase the analgesic activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of serotonin syndrome can be increased when Buspirone is combined with Lisdexamfetamine.]
[N02AF01, butorphanol, Lisdexamfetamine may increase the analgesic activities of Butorphanol.]
[R06AX09, azatadine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Azatadine.]
[S01GX07, azelastine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Lisdexamfetamine can be decreased when combined with Rucaparib.]
[A07EC04, balsalazide, The risk or severity of hypertension can be increased when Balsalazide is combined with Lisdexamfetamine.]
[R03CC12, bambuterol, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Bambuterol.]
[R03DA08, bamifylline, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Bamifylline.]
[N07XX16, deutetrabenazine, The metabolism of Deutetrabenazine can be decreased when combined with Lisdexamfetamine.]
[N06BC01, caffeine, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Caffeine.]
[C09AA07, benazepril, Lisdexamfetamine may decrease the antihypertensive activities of Benazepril.]
[A12AA04, calcium carbonate, The serum concentration of Lisdexamfetamine can be increased when it is combined with Calcium carbonate.]
[J01XX08, linezolid, The risk or severity of hypertension can be increased when Linezolid is combined with Lisdexamfetamine.]
[J05AE09, tipranavir, The metabolism of Lisdexamfetamine can be decreased when combined with Tipranavir.]
[H03BA03, benzylthiouracil, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Benzylthiouracil.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Lisdexamfetamine.]
[L04AB02, infliximab, The metabolism of Lisdexamfetamine can be increased when combined with Infliximab.]
[H05AA04, abaloparatide, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Abaloparatide.]
[N04BD03, safinamide, Safinamide may increase the hypertensive activities of Lisdexamfetamine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Lisdexamfetamine.]
[A02BX12, bismuth subnitrate, The serum concentration of Lisdexamfetamine can be increased when it is combined with Bismuth subnitrate.]
[C07AB07, bisoprolol, The therapeutic efficacy of Bisoprolol can be decreased when used in combination with Lisdexamfetamine.]
[R03AC17, bitolterol, The risk or severity of hypertension can be increased when Bitolterol is combined with Lisdexamfetamine.]
[C07AA17, bopindolol, The therapeutic efficacy of Bopindolol can be decreased when used in combination with Lisdexamfetamine.]
[N04AA11, bornaprine, The risk or severity of Tachycardia can be increased when Lisdexamfetamine is combined with Bornaprine.]
[N05AD06, bromperidol, Bromperidol may decrease the stimulatory activities of Lisdexamfetamine.]
[C04AX20, buflomedil, The therapeutic efficacy of Buflomedil can be decreased when used in combination with Lisdexamfetamine.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Bumadizone.]
[J05AX18, letermovir, The metabolism of Letermovir can be decreased when combined with Lisdexamfetamine.]
[N06AA15, butriptyline, Lisdexamfetamine may decrease the sedative and stimulatory activities of Butriptyline.]
[R06AX18, acrivastine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Acrivastine.]
[C09AA01, captopril, Lisdexamfetamine may decrease the antihypertensive activities of Captopril.]
[N03AF01, carbamazepine, The risk or severity of serotonin syndrome can be increased when Carbamazepine is combined with Lisdexamfetamine.]
[A03AA03, camylofine, The risk or severity of Tachycardia can be increased when Lisdexamfetamine is combined with Camylofin.]
[H03BB01, carbimazole, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Carbimazole.]
[R06AA08, carbinoxamine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Carbinoxamine.]
[C07AG02, carvedilol, The therapeutic efficacy of Carvedilol can be decreased when used in combination with Lisdexamfetamine.]
[N03AX24, cannabidiol, The metabolism of Lisdexamfetamine can be decreased when combined with Cannabidiol.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Lisdexamfetamine.]
[C07AB08, celiprolol, The therapeutic efficacy of Celiprolol can be decreased when used in combination with Lisdexamfetamine.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Lisdexamfetamine.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Lisdexamfetamine.]
[N03AX17, stiripentol, The metabolism of Lisdexamfetamine can be decreased when combined with Stiripentol.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Lisdexamfetamine.]
[S01GX12, cetirizine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Cetirizine.]
[R06AC03, chloropyramine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Chloropyramine.]
[R06AA06, chlorphenoxamine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Lornoxicam.]
[R03DA02, oxtriphylline, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Oxtriphylline.]
[R03BB08, revefenacin, The metabolism of Revefenacin can be decreased when combined with Lisdexamfetamine.]
[L04AA39, emapalumab, The metabolism of Lisdexamfetamine can be increased when combined with Emapalumab.]
[C09AA08, cilazapril, Lisdexamfetamine may decrease the antihypertensive activities of Cilazapril.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Lisdexamfetamine.]
[A03FA08, cinitapride, The risk or severity of serotonin syndrome can be increased when Lisdexamfetamine is combined with Cinitapride.]
[A09AB04, citric acid, The excretion of Lisdexamfetamine can be decreased when combined with Citric acid.]
[P02BX04, triclabendazole, The metabolism of Lisdexamfetamine can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Lisdexamfetamine.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Siponimod.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Lisdexamfetamine.]
[N05BA09, clobazam, The metabolism of Lisdexamfetamine can be decreased when combined with Clobazam.]
[R05DB10, chlophedianol, Lisdexamfetamine may decrease the sedative and stimulatory activities of Clofedanol.]
[C09CA06, candesartan, Lisdexamfetamine may decrease the antihypertensive activities of Candesartan.]
[L04AB01, etanercept, The metabolism of Lisdexamfetamine can be increased when combined with Etanercept.]
[N05AA06, cyamemazine, Cyamemazine may decrease the stimulatory activities of Lisdexamfetamine.]
[C03BX03, cicletanine, Lisdexamfetamine may decrease the antihypertensive activities of Cicletanine.]
[M03BX08, cyclobenzaprine, The risk or severity of serotonin syndrome can be increased when Cyclobenzaprine is combined with Lisdexamfetamine.]
[L01EJ02, fedratinib, The metabolism of Lisdexamfetamine can be decreased when combined with Fedratinib.]
[N07XX11, pitolisant, Lisdexamfetamine may decrease the sedative and stimulatory activities of Pitolisant.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Lisdexamfetamine.]
[C03AA09, cyclothiazide, Lisdexamfetamine may decrease the antihypertensive activities of Cyclothiazide.]
[G04BE04, yohimbine, The therapeutic efficacy of Yohimbine can be decreased when used in combination with Lisdexamfetamine.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Lisdexamfetamine.]
[A16AX16, givosiran, The serum concentration of Lisdexamfetamine can be increased when it is combined with Givosiran.]
[R06AB06, dexbrompheniramine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Dexbrompheniramine.]
[R06AB02, dexchlorpheniramine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Dexchlorpheniramine.]
[N02AX03, dezocine, Lisdexamfetamine may increase the analgesic activities of Dezocine.]
[N05AD10, lumateperone, Lumateperone may decrease the stimulatory activities of Lisdexamfetamine.]
[M01AX21, diacetylrhein, The metabolism of Lisdexamfetamine can be decreased when combined with Diacerein.]
[H02CA02, osilodrostat, The metabolism of Lisdexamfetamine can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Amprenavir can be decreased when combined with Lisdexamfetamine.]
[N02CC07, frovatriptan, The risk or severity of serotonin syndrome can be increased when Frovatriptan is combined with Lisdexamfetamine.]
[G04CB02, dutasteride, The therapeutic efficacy of Dutasteride can be decreased when used in combination with Lisdexamfetamine.]
[N02AA08, dihydrocodeine, Lisdexamfetamine may increase the analgesic activities of Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of serotonin syndrome can be increased when Eletriptan is combined with Lisdexamfetamine.]
[M01AH02, rofecoxib, The risk or severity of hypertension can be increased when Rofecoxib is combined with Lisdexamfetamine.]
[C08CA16, clevidipine, The metabolism of Clevidipine can be decreased when combined with Lisdexamfetamine.]
[C01BD07, dronedarone, The metabolism of Lisdexamfetamine can be decreased when combined with Dronedarone.]
[R06AA07, diphenylpyraline, Lisdexamfetamine may decrease the sedative and stimulatory activities of Diphenylpyraline.]
[R06AE04, chlorcyclizine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Chlorcyclizine.]
[C02AA06, methoserpidine, Lisdexamfetamine may decrease the antihypertensive activities of Methoserpidine.]
[A03AA08, dihexyverine, The risk or severity of Tachycardia can be increased when Lisdexamfetamine is combined with Dihexyverine.]
[C01CA14, dopexamine, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Dopexamine.]
[G04BD09, trospium, The metabolism of Lisdexamfetamine can be decreased when combined with Trospium.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Droxicam.]
[L01EX22, selpercatinib, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Selpercatinib.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Dexketoprofen.]
[C08CA17, levamlodipine, Lisdexamfetamine may decrease the antihypertensive activities of Levamlodipine.]
[R06AX22, ebastine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Ebastine.]
[P01BB01, proguanil, The metabolism of Lisdexamfetamine can be decreased when combined with Proguanil.]
[N02AX07, oliceridine, The risk or severity of serotonin syndrome can be increased when Lisdexamfetamine is combined with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Lisdexamfetamine can be decreased when combined with Chloroquine.]
[C03AA04, chlorothiazide, Lisdexamfetamine may decrease the antihypertensive activities of Chlorothiazide.]
[R06AB04, chlorpheniramine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Chlorpheniramine.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Lisdexamfetamine can be decreased when used in combination with Chlorpromazine.]
[N05AF03, chlorprothixene, Lisdexamfetamine may decrease the sedative and stimulatory activities of Chlorprothixene.]
[C03BA04, chlorthalidone, Lisdexamfetamine may decrease the antihypertensive activities of Chlorthalidone.]
[M03BB03, chlorzoxazone, The metabolism of Chlorzoxazone can be decreased when combined with Lisdexamfetamine.]
[A11CC05, cholecalciferol, The metabolism of Lisdexamfetamine can be decreased when combined with Cholecalciferol.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Ethenzamide.]
[M01AB08, etodolac, The risk or severity of hypertension can be increased when Etodolac is combined with Lisdexamfetamine.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Lisdexamfetamine can be decreased when combined with Berotralstat.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Naxitamab.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Fenbufen.]
[N06BA10, fenethylline, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Fenethylline.]
[C01CA19, fenoldopam, Lisdexamfetamine may decrease the antihypertensive activities of Fenoldopam.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Finasteride is combined with Lisdexamfetamine.]
[R03CC15, formoterol, The risk or severity of hypertension can be increased when Formoterol is combined with Lisdexamfetamine.]
[N01AB05, trichloroethylene, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The metabolism of Lisdexamfetamine can be decreased when combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, Lisdexamfetamine may decrease the antihypertensive activities of Dasiglucagon.]
[G03GA06, follitropin beta, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Follitropin.]
[A02BA01, cimetidine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Cimetidine.]
[N07CA02, cinnarizine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Cinnarizine.]
[N06AB04, citalopram, The metabolism of Lisdexamfetamine can be decreased when combined with Citalopram.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be decreased when combined with Lisdexamfetamine.]
[V09AB03, ioflupane I-123, Lisdexamfetamine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.]
[R06AA04, clemastine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Clemastine.]
[M01AG01, mefenamic acid, The risk or severity of hypertension can be increased when Mefenamic acid is combined with Lisdexamfetamine.]
[R03CC13, clenbuterol, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Clenbuterol.]
[N06AX25, St. John's wort extract, The risk or severity of serotonin syndrome can be increased when Lisdexamfetamine is combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The metabolism of Lisdexamfetamine can be decreased when combined with Ropeginterferon alfa-2b.]
[N06AA04, clomipramine, The therapeutic efficacy of Clomipramine can be increased when used in combination with Lisdexamfetamine.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Lisdexamfetamine.]
[N05AH06, clothiapine, Clothiapine may decrease the stimulatory activities of Lisdexamfetamine.]
[A04AA01, ondansetron, The risk or severity of serotonin syndrome can be increased when Ondansetron is combined with Lisdexamfetamine.]
[A04AA02, granisetron, The risk or severity of serotonin syndrome can be increased when Granisetron is combined with Lisdexamfetamine.]
[N05AH02, clozapine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Clozapine.]
[S02DA02, cocaine, The metabolism of Lisdexamfetamine can be decreased when combined with Cocaine.]
[C02KB01, metyrosine, Lisdexamfetamine may decrease the antihypertensive activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Lisdexamfetamine can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Proquazone.]
[R05DA04, codeine, Lisdexamfetamine may increase the analgesic activities of Codeine.]
[A03AB10, hexocyclium, The risk or severity of Tachycardia can be increased when Lisdexamfetamine is combined with Hexocyclium.]
[A03BB06, homatropine methylbromide, The risk or severity of Tachycardia can be increased when Homatropine methylbromide is combined with Lisdexamfetamine.]
[A02AD04, hydrotalcite, The serum concentration of Lisdexamfetamine can be increased when it is combined with Hydrotalcite.]
[N01AB07, desflurane, The risk or severity of hypertension can be increased when Desflurane is combined with Lisdexamfetamine.]
[C04AX28, ifenprodil, The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Lisdexamfetamine.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be decreased when combined with Lisdexamfetamine.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Imidazole salicylate.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be decreased when combined with Lisdexamfetamine.]
[B01AC10, indobufen, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Indobufen.]
[R06AX27, desloratadine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Desloratadine.]
[M01AH03, valdecoxib, The risk or severity of hypertension can be increased when Valdecoxib is combined with Lisdexamfetamine.]
[A03AX10, isometheptene, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Isometheptene.]
[N02CC05, almotriptan, The risk or severity of serotonin syndrome can be increased when Almotriptan is combined with Lisdexamfetamine.]
[M01AH04, parecoxib, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Parecoxib.]
[R06AD09, isothipendyl, Lisdexamfetamine may decrease the sedative and stimulatory activities of Isothipendyl.]
[S01GX06, emedastine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Emedastine.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Kebuzone.]
[L01EA01, imatinib, The serum concentration of Lisdexamfetamine can be increased when it is combined with Imatinib.]
[C08CA09, lacidipine, Lisdexamfetamine may decrease the antihypertensive activities of Lacidipine.]
[N03AX09, lamotrigine, The therapeutic efficacy of Lamotrigine can be decreased when used in combination with Lisdexamfetamine.]
[N07BC04, lofexidine, The risk or severity of serotonin syndrome can be increased when Lisdexamfetamine is combined with Lofexidine.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Lonazolac.]
[R06AX13, loratadine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Loratadine.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Loxoprofen.]
[C09AA03, lisinopril, Lisdexamfetamine may decrease the antihypertensive activities of Lisinopril.]
[A02AD02, magaldrate, The serum concentration of Lisdexamfetamine can be increased when it is combined with Magaldrate.]
[A06AD01, magnesium carbonate, The serum concentration of Lisdexamfetamine can be increased when it is combined with Magnesium carbonate.]
[C08CA11, manidipine, The metabolism of Lisdexamfetamine can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, The risk or severity of Tachycardia can be increased when Lisdexamfetamine is combined with Mebeverine.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Mefenorex.]
[C07AA14, mepindolol, The therapeutic efficacy of Mepindolol can be decreased when used in combination with Lisdexamfetamine.]
[R06AD07, mequitazine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Mequitazine.]
[C01EB10, adenosine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Lisdexamfetamine.]
[R06AD04, methdilazine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Methdilazine.]
[N04AA03, methixene, The risk or severity of Tachycardia can be increased when Metixene is combined with Lisdexamfetamine.]
[R03CB02, methoxyphenamine, The risk or severity of serotonin syndrome can be increased when Lisdexamfetamine is combined with Methoxyphenamine.]
[R06AE03, cyclizine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Cyclizine.]
[C03DA04, eplerenone, Lisdexamfetamine may decrease the antihypertensive activities of Eplerenone.]
[N05AD03, metylperon, Melperone may decrease the stimulatory activities of Lisdexamfetamine.]
[C03AA07, cyclopenthiazide, Lisdexamfetamine may decrease the antihypertensive activities of Cyclopenthiazide.]
[N06AX07, minaprine, Minaprine may increase the hypertensive activities of Lisdexamfetamine.]
[S01XA18, cyclosporine, The metabolism of Lisdexamfetamine can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the hypertensive activities of Lisdexamfetamine.]
[N06BA07, modafinil, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Modafinil.]
[R06AX02, cyproheptadine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Cyproheptadine.]
[C09AA13, moexipril, Lisdexamfetamine may decrease the antihypertensive activities of Moexipril.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Morniflumate.]
[C02AC05, moxonidine, Lisdexamfetamine may decrease the antihypertensive activities of Moxonidine.]
[M01AH05, etoricoxib, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Etoricoxib.]
[C02CC04, debrisoquin, Lisdexamfetamine may decrease the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of Tachycardia can be increased when Nabilone is combined with Lisdexamfetamine.]
[M01AX01, nabumetone, The risk or severity of hypertension can be increased when Nabumetone is combined with Lisdexamfetamine.]
[C07AB12, nebivolol, The therapeutic efficacy of Nebivolol can be decreased when used in combination with Lisdexamfetamine.]
[N06AX06, nefazodone, The therapeutic efficacy of Nefazodone can be decreased when used in combination with Lisdexamfetamine.]
[C01DX16, nicorandil, Lisdexamfetamine may decrease the antihypertensive activities of Nicorandil.]
[C01CA23, theodrenaline, The therapeutic efficacy of Lisdexamfetamine can be increased when used in combination with Theodrenaline.]
[C01CA05, norfenefrine, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Norfenefrine.]
[R05DA06, normethadone, Lisdexamfetamine may increase the analgesic activities of Normethadone.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Lisdexamfetamine is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Solifenacin.]
[A07EC03, olsalazine, The risk or severity of hypertension can be increased when Olsalazine is combined with Lisdexamfetamine.]
[N06AA01, desipramine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Desipramine.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Lisdexamfetamine.]
[C09XA02, aliskiren, Lisdexamfetamine may decrease the antihypertensive activities of Aliskiren.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Oxaprozin is combined with Lisdexamfetamine.]
[N04AA08, dexetimide, The risk or severity of Tachycardia can be increased when Lisdexamfetamine is combined with Dexetimide.]
[G04BD04, oxybutynin, The metabolism of Lisdexamfetamine can be decreased when combined with Oxybutynin.]
[A08AA04, dexfenfluramine, The risk or severity of serotonin syndrome can be increased when Dexfenfluramine is combined with Lisdexamfetamine.]
[A03AA01, oxyphencyclimine, The risk or severity of Tachycardia can be increased when Oxyphencyclimine is combined with Lisdexamfetamine.]
[L04AB04, adalimumab, The metabolism of Lisdexamfetamine can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Lisdexamfetamine can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Lisdexamfetamine.]
[R05DA09, dextromethorphan, The risk or severity of serotonin syndrome can be increased when Dextromethorphan is combined with Lisdexamfetamine.]
[N02AC01, dextromoramide, Lisdexamfetamine may increase the analgesic activities of Dextromoramide.]
[H05AA02, teriparatide, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Teriparatide.]
[N06AB05, paroxetine, The metabolism of Lisdexamfetamine can be decreased when combined with Paroxetine.]
[N07BC06, heroin, Lisdexamfetamine may increase the analgesic activities of Diamorphine.]
[C04AD01, pentifylline, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Pentifylline.]
[V03AH01, diazoxide, Lisdexamfetamine may decrease the antihypertensive activities of Diazoxide.]
[R06AX04, phenindamine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Phenindamine.]
[N06AA08, dibenzepin, The therapeutic efficacy of Dibenzepin can be increased when used in combination with Lisdexamfetamine.]
[S01EC02, dichlorphenamide, Diclofenamide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.]
[S01BC03, diclofenac, The risk or severity of hypertension can be increased when Diclofenac is combined with Lisdexamfetamine.]
[A03AA07, dicyclomine, The risk or severity of Tachycardia can be increased when Dicyclomine is combined with Lisdexamfetamine.]
[C02DG01, pinacidil, Lisdexamfetamine may decrease the antihypertensive activities of Pinacidil.]
[N05AD05, pipamperone, Pipamperone may decrease the stimulatory activities of Lisdexamfetamine.]
[A03AB14, pipenzolate, The risk or severity of Tachycardia can be increased when Lisdexamfetamine is combined with Pipenzolate.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Lisdexamfetamine.]
[R03CC07, pirbuterol, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Pirbuterol.]
[A08AA03, diethylpropion, The risk or severity of serotonin syndrome can be increased when Diethylpropion is combined with Lisdexamfetamine.]
[C08CA03, isradipine, Lisdexamfetamine may decrease the antihypertensive activities of Isradipine.]
[A03AB11, poldine, The risk or severity of Tachycardia can be increased when Lisdexamfetamine is combined with Poldine.]
[N02BA11, diflunisal, The risk or severity of hypertension can be increased when Diflunisal is combined with Lisdexamfetamine.]
[C02DB01, dihydralazine, Lisdexamfetamine may decrease the antihypertensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, The therapeutic efficacy of Dihydroergocristine can be decreased when used in combination with Lisdexamfetamine.]
[N02CA01, dihydroergotamine, The therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Lisdexamfetamine.]
[N02AA03, hydromorphone, Lisdexamfetamine may increase the analgesic activities of Hydromorphone.]
[B01AC21, treprostinil, Lisdexamfetamine may decrease the antihypertensive activities of Treprostinil.]
[H03BC01, potassium perchlorate, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Potassium perchlorate.]
[C08DB01, diltiazem, Lisdexamfetamine may decrease the antihypertensive activities of Diltiazem.]
[R06AA11, dimenhydrinate, Lisdexamfetamine may decrease the sedative and stimulatory activities of Dimenhydrinate.]
[R06AB03, dimethindene, Lisdexamfetamine may decrease the sedative and stimulatory activities of Dimetindene.]
[R03CC08, procaterol, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Procaterol.]
[M02AX03, dimethyl sulfoxide, The metabolism of Lisdexamfetamine can be decreased when combined with Dimethyl sulfoxide.]
[N06BC02, propentofylline, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Propentofylline.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Proglumetacin.]
[R03DA03, proxyphylline, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Proxyphylline.]
[R06AA02, diphenhydramine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Diphenhydramine.]
[A07DA01, diphenoxylate, Lisdexamfetamine may increase the analgesic activities of Diphenoxylate.]
[C09AA06, quinapril, Lisdexamfetamine may decrease the antihypertensive activities of Quinapril.]
[N06BA11, dexmethylphenidate, The risk or severity of serotonin syndrome can be increased when Lisdexamfetamine is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The therapeutic efficacy of Quinupramine can be increased when used in combination with Lisdexamfetamine.]
[A03FA02, cisapride, The metabolism of Lisdexamfetamine can be decreased when combined with Cisapride.]
[C09AA05, ramipril, Lisdexamfetamine may decrease the antihypertensive activities of Ramipril.]
[N05AL04, remoxipride, Remoxipride may decrease the stimulatory activities of Lisdexamfetamine.]
[R03CC14, reproterol, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Reproterol.]
[C01BA03, disopyramide, The risk or severity of Tachycardia can be increased when Disopyramide is combined with Lisdexamfetamine.]
[P03AA04, disulfiram, The therapeutic efficacy of Lisdexamfetamine can be decreased when used in combination with Disulfiram.]
[N05AX08, risperidone, Lisdexamfetamine may decrease the sedative and stimulatory activities of Risperidone.]
[R06AE09, levocetirizine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Levocetirizine.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Lisdexamfetamine.]
[G04BE08, tadalafil, Lisdexamfetamine may decrease the antihypertensive activities of Tadalafil.]
[S01BC05, ketorolac, The risk or severity of hypertension can be increased when Ketorolac is combined with Lisdexamfetamine.]
[C02KX02, ambrisentan, Lisdexamfetamine may decrease the antihypertensive activities of Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Lisdexamfetamine can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of hypertension can be increased when Salmeterol is combined with Lisdexamfetamine.]
[H05BA01, salmon calcitonin, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Salmon calcitonin.]
[C01CA07, dobutamine, The risk or severity of hypertension can be increased when Dobutamine is combined with Lisdexamfetamine.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Lisdexamfetamine.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Dopamine is combined with Lisdexamfetamine.]
[N06AA16, dothiepin, Lisdexamfetamine may decrease the sedative and stimulatory activities of Dosulepin.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Doxapram is combined with Lisdexamfetamine.]
[N06AA12, doxepin, Lisdexamfetamine may decrease the sedative and stimulatory activities of Doxepin.]
[L01DB01, doxorubicin, The metabolism of Lisdexamfetamine can be decreased when combined with Doxorubicin.]
[R06AA09, doxylamine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Doxylamine.]
[N06AB06, sertraline, The risk or severity of serotonin syndrome can be increased when Sertraline is combined with Lisdexamfetamine.]
[N01AB08, sevoflurane, The risk or severity of hypertension can be increased when Sevoflurane is combined with Lisdexamfetamine.]
[N05AD08, droperidol, The therapeutic efficacy of Droperidol can be decreased when used in combination with Lisdexamfetamine.]
[A08AA10, sibutramine, The risk or severity of serotonin syndrome can be increased when Sibutramine is combined with Lisdexamfetamine.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Lisdexamfetamine.]
[B05XA02, sodium bicarbonate, The serum concentration of Lisdexamfetamine can be increased when it is combined with Sodium bicarbonate.]
[V03AG05, sodium phosphate, The serum concentration of Lisdexamfetamine can be decreased when it is combined with Sodium phosphate, monobasic.]
[C09AA11, spirapril, Lisdexamfetamine may decrease the antihypertensive activities of Spirapril.]
[R03DA01, dyphylline, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Dyphylline.]
[N05AL02, sultopride, Sultopride may decrease the stimulatory activities of Lisdexamfetamine.]
[N02CC01, sumatriptan, The risk or severity of serotonin syndrome can be increased when Sumatriptan is combined with Lisdexamfetamine.]
[C07AB13, talinolol, The therapeutic efficacy of Talinolol can be decreased when used in combination with Lisdexamfetamine.]
[M01AC02, tenoxicam, The risk or severity of hypertension can be increased when Tenoxicam is combined with Lisdexamfetamine.]
[G04CA03, terazosin, The therapeutic efficacy of Terazosin can be decreased when used in combination with Lisdexamfetamine.]
[D01BA02, terbinafine, The metabolism of Lisdexamfetamine can be decreased when combined with Terbinafine.]
[C07AA16, tertatolol, The therapeutic efficacy of Tertatolol can be decreased when used in combination with Lisdexamfetamine.]
[S01GA02, tetrahydrozoline, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Tetryzoline.]
[N05AB05, thiopropazate, Thiopropazate may decrease the stimulatory activities of Lisdexamfetamine.]
[G04BD01, emepronium, The risk or severity of Tachycardia can be increased when Lisdexamfetamine is combined with Emepronium.]
[N06AX14, tianeptine, The therapeutic efficacy of Tianeptine can be increased when used in combination with Lisdexamfetamine.]
[C09AA02, enalapril, Lisdexamfetamine may decrease the antihypertensive activities of Enalapril.]
[M01AG02, tolfenamic acid, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the hypertensive activities of Lisdexamfetamine.]
[N06BA09, atomoxetine, The metabolism of Atomoxetine can be decreased when combined with Lisdexamfetamine.]
[C03CA04, torsemide, Lisdexamfetamine may decrease the antihypertensive activities of Torasemide.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Tramazoline.]
[C09AA10, trandolapril, Lisdexamfetamine may decrease the antihypertensive activities of Trandolapril.]
[A03AB08, tridihexethyl, The risk or severity of Tachycardia can be increased when Tridihexethyl is combined with Lisdexamfetamine.]
[G03GA05, follitropin alfa, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Follitropin.]
[R06AX21, tritoqualine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Tritoqualine.]
[N04AA12, tropatepine, The risk or severity of Tachycardia can be increased when Lisdexamfetamine is combined with Tropatepine.]
[R03CC11, tulobuterol, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Tulobuterol.]
[C02CA06, urapidil, The therapeutic efficacy of Urapidil can be decreased when used in combination with Lisdexamfetamine.]
[N05AL06, veralipride, Veralipride may decrease the stimulatory activities of Lisdexamfetamine.]
[L01CA04, vinorelbine, The metabolism of Lisdexamfetamine can be decreased when combined with Vinorelbine.]
[S01FB02, ephedrine, The therapeutic efficacy of Lisdexamfetamine can be increased when used in combination with Ephedrine.]
[S01GX10, epinastine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Epinastine.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Lisdexamfetamine is combined with Venlafaxine.]
[C01CX07, xamoterol, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Xamoterol.]
[S01GA03, xylometazoline, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Xylometazoline.]
[S01EA01, epinephrine, The therapeutic efficacy of Lisdexamfetamine can be increased when used in combination with Epinephrine.]
[C09AA15, zofenopril, Lisdexamfetamine may decrease the antihypertensive activities of Zofenopril.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be decreased when combined with Lisdexamfetamine.]
[M01AB04, zomepirac, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Zomepirac.]
[N03AX15, zonisamide, Zonisamide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.]
[N05AX11, zotepine, Zotepine may decrease the stimulatory activities of Lisdexamfetamine.]
[C02AC02, guanfacine, Lisdexamfetamine may decrease the antihypertensive activities of Guanfacine.]
[C01BG01, moricizine, Moricizine may decrease the stimulatory activities of Lisdexamfetamine.]
[G02AB03, ergonovine, The risk or severity of serotonin syndrome can be increased when Ergometrine is combined with Lisdexamfetamine.]
[C04AE01, ergoloid mesylates, USP, The therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with Lisdexamfetamine.]
[N02CA02, ergotamine, The therapeutic efficacy of Ergotamine can be decreased when used in combination with Lisdexamfetamine.]
[N03AG01, valproic acid, The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Lisdexamfetamine.]
[H05BX01, cinacalcet, The metabolism of Lisdexamfetamine can be decreased when combined with Cinacalcet.]
[J04AK02, ethambutol, The metabolism of Lisdexamfetamine can be decreased when combined with Ethambutol.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Lisdexamfetamine.]
[C01CA15, gepefrine, The risk or severity of serotonin syndrome can be increased when Lisdexamfetamine is combined with Gepefrine.]
[N04AA05, profenamine, The therapeutic efficacy of Profenamine can be decreased when used in combination with Lisdexamfetamine.]
[N03AD01, ethosuximide, Lisdexamfetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M01AC06, meloxicam, The risk or severity of hypertension can be increased when Meloxicam is combined with Lisdexamfetamine.]
[S01XA06, ethylmorphine, Lisdexamfetamine may increase the analgesic activities of Ethylmorphine.]
[C01CA01, etilefrine, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Etilefrine.]
[N01AX07, etomidate, The risk or severity of hypertension can be increased when Etomidate is combined with Lisdexamfetamine.]
[N05AE03, sertindole, Sertindole may decrease the stimulatory activities of Lisdexamfetamine.]
[A02BA04, nizatidine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Nizatidine.]
[R06AX11, astemizole, Lisdexamfetamine may decrease the sedative and stimulatory activities of Astemizole.]
[R06AX12, terfenadine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Terfenadine.]
[N06AX12, bupropion, The metabolism of Lisdexamfetamine can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Lisdexamfetamine can be decreased when combined with Fluvoxamine.]
[C01BC08, encainide, The metabolism of Encainide can be decreased when combined with Lisdexamfetamine.]
[A02BA03, famotidine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Famotidine.]
[C08CA02, felodipine, The metabolism of Lisdexamfetamine can be decreased when combined with Felodipine.]
[N03AX26, fenfluramine, The risk or severity of serotonin syndrome can be increased when Lisdexamfetamine is combined with Fenfluramine.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Fenoprofen is combined with Lisdexamfetamine.]
[R03CC04, fenoterol, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Fenoterol.]
[N02AB03, fentanyl, Lisdexamfetamine may increase the analgesic activities of Fentanyl.]
[R03CC02, albuterol, The risk or severity of hypertension can be increased when Salbutamol is combined with Lisdexamfetamine.]
[B03AA10, ferrous ascorbate, The serum concentration of Lisdexamfetamine can be decreased when it is combined with Ferrous ascorbate.]
[N07AX03, cevimeline, The metabolism of Cevimeline can be decreased when combined with Lisdexamfetamine.]
[G04BD02, flavoxate, The risk or severity of Tachycardia can be increased when Flavoxate is combined with Lisdexamfetamine.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Lisdexamfetamine.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Floctafenine.]
[N07CA03, flunarizine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Flunarizine.]
[N06AA14, melitracen, The therapeutic efficacy of Melitracen can be increased when used in combination with Lisdexamfetamine.]
[N06AB03, fluoxetine, The serum concentration of Lisdexamfetamine can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, The therapeutic efficacy of Flupentixol can be decreased when used in combination with Lisdexamfetamine.]
[N05AB02, fluphenazine, Fluphenazine may decrease the stimulatory activities of Lisdexamfetamine.]
[S01BC04, flurbiprofen, The risk or severity of hypertension can be increased when Flurbiprofen is combined with Lisdexamfetamine.]
[N05AG01, fluspirilene, Fluspirilene may decrease the stimulatory activities of Lisdexamfetamine.]
[N06BX17, adrafinil, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Adrafinil.]
[G01AX06, furazolidone, Furazolidone may increase the hypertensive activities of Lisdexamfetamine.]
[J05AE10, darunavir, The metabolism of Lisdexamfetamine can be decreased when combined with Darunavir.]
[C03CA01, furosemide, Lisdexamfetamine may decrease the antihypertensive activities of Furosemide.]
[N05AL05, amisulpride, Amisulpride may decrease the stimulatory activities of Lisdexamfetamine.]
[N06DA04, galantamine, The metabolism of Galantamine can be decreased when combined with Lisdexamfetamine.]
[N06AX08, bifemelane, The risk or severity of serotonin syndrome can be increased when Lisdexamfetamine is combined with Bifemelane.]
[N04BC06, cabergoline, The risk or severity of serotonin syndrome can be increased when Cabergoline is combined with Lisdexamfetamine.]
[C01CA21, cafedrine, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Cafedrine.]
[N01AH02, alfentanil, Lisdexamfetamine may increase the analgesic activities of Alfentanil.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Lisdexamfetamine.]
[N05CM18, dexmedetomidine, The metabolism of Lisdexamfetamine can be decreased when combined with Dexmedetomidine.]
[C05AE01, nitroglycerin, Lisdexamfetamine may decrease the antihypertensive activities of Nitroglycerin.]
[C02CA04, doxazosin, The therapeutic efficacy of Doxazosin can be decreased when used in combination with Lisdexamfetamine.]
[H01AB01, thyrotropin alfa, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Thyrotropin alfa.]
[C07AB09, esmolol, The therapeutic efficacy of Esmolol can be decreased when used in combination with Lisdexamfetamine.]
[N02CX05, fonazine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Dimetotiazine.]
[C09AA09, fosinopril, Lisdexamfetamine may decrease the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, The serum concentration of Lisdexamfetamine can be decreased when it is combined with Guanethidine.]
[P01BX01, halofantrine, The metabolism of Lisdexamfetamine can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The therapeutic efficacy of Lisdexamfetamine can be decreased when used in combination with Haloperidol.]
[N01AB01, halothane, The risk or severity of hypertension can be increased when Halothane is combined with Lisdexamfetamine.]
[N05AH04, quetiapine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Quetiapine.]
[C09CA01, losartan, Lisdexamfetamine may decrease the antihypertensive activities of Losartan.]
[A07EC02, mesalamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Lisdexamfetamine.]
[R03CC05, hexoprenaline, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Hexoprenaline.]
[J05AG01, nevirapine, The metabolism of Lisdexamfetamine can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, Lisdexamfetamine may decrease the antihypertensive activities of Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Nimesulide.]
[R06AE06, oxatomide, Lisdexamfetamine may decrease the sedative and stimulatory activities of Oxatomide.]
[C09AA04, perindopril, Lisdexamfetamine may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Lisdexamfetamine may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, Lisdexamfetamine may decrease the antihypertensive activities of Hydrochlorothiazide.]
[R05DA03, hydrocodone, The risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Lisdexamfetamine.]
[C03AA02, hydroflumethiazide, Lisdexamfetamine may decrease the antihypertensive activities of Hydroflumethiazide.]
[A12BA02, potassium citrate, The excretion of Lisdexamfetamine can be decreased when combined with Potassium citrate.]
[G04BD06, propiverine, The therapeutic efficacy of Propiverine can be decreased when used in combination with Lisdexamfetamine.]
[P01BA02, hydroxychloroquine, The metabolism of Lisdexamfetamine can be decreased when combined with Hydroxychloroquine.]
[N05AX07, prothipendyl, Prothipendyl may decrease the stimulatory activities of Lisdexamfetamine.]
[N05BB01, hydroxyzine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Hydroxyzine.]
[C02AC06, rilmenidine, Lisdexamfetamine may decrease the antihypertensive activities of Rilmenidine.]
[R02AX02, ibuprofen, The risk or severity of hypertension can be increased when Ibuprofen is combined with Lisdexamfetamine.]
[B05CB02, sodium citrate, The excretion of Lisdexamfetamine can be decreased when combined with Sodium citrate.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Lisdexamfetamine.]
[N01AH03, sufentanil, Lisdexamfetamine may increase the analgesic activities of Sufentanil.]
[N06AA02, imipramine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Imipramine.]
[M03BX02, tizanidine, The risk or severity of Tachycardia can be increased when Tizanidine is combined with Lisdexamfetamine.]
[C03BA11, indapamide, Lisdexamfetamine may decrease the antihypertensive activities of Indapamide.]
[S01BC01, indomethacin, The risk or severity of hypertension can be increased when Indomethacin is combined with Lisdexamfetamine.]
[C02CA02, indoramin, The therapeutic efficacy of Indoramin can be decreased when used in combination with Lisdexamfetamine.]
[N06AX17, milnacipran, The risk or severity of serotonin syndrome can be increased when Lisdexamfetamine is combined with Milnacipran.]
[A03AA30, piperidolate, The risk or severity of Tachycardia can be increased when Lisdexamfetamine is combined with Piperidolate.]
[R06AE01, buclizine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Buclizine.]
[C10AA06, cerivastatin, The metabolism of Lisdexamfetamine can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of Tachycardia can be increased when Anagrelide is combined with Lisdexamfetamine.]
[C07AA01, alprenolol, The therapeutic efficacy of Alprenolol can be decreased when used in combination with Lisdexamfetamine.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Lisdexamfetamine.]
[N06AA13, iprindole, The therapeutic efficacy of Iprindole can be increased when used in combination with Lisdexamfetamine.]
[N06AF05, iproniazid, Iproniazid may increase the hypertensive activities of Lisdexamfetamine.]
[N05AA07, chlorproethazine, Chlorproethazine may decrease the stimulatory activities of Lisdexamfetamine.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the hypertensive activities of Lisdexamfetamine.]
[R03CC06, isoetharine, The risk or severity of hypertension can be increased when Isoetharine is combined with Lisdexamfetamine.]
[C09AA16, imidapril, Lisdexamfetamine may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of hypertension can be increased when Isoflurane is combined with Lisdexamfetamine.]
[N04BX02, entacapone, The metabolism of Lisdexamfetamine can be decreased when combined with Entacapone.]
[J04AC01, isoniazid, The risk or severity of serotonin syndrome can be increased when Isoniazid is combined with Lisdexamfetamine.]
[R03CB01, isoproterenol, The risk or severity of hypertension can be increased when Isoprenaline is combined with Lisdexamfetamine.]
[C04AA01, isoxsuprine, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Isoxsuprine.]
[N06AX18, reboxetine, The metabolism of Lisdexamfetamine can be decreased when combined with Reboxetine.]
[A02AB01, aluminum hydroxide, The serum concentration of Lisdexamfetamine can be increased when it is combined with Aluminum hydroxide.]
[L04AC07, tocilizumab, The metabolism of Lisdexamfetamine can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of Tachycardia can be increased when Ketamine is combined with Lisdexamfetamine.]
[C02KD01, ketanserin, The risk or severity of serotonin syndrome can be increased when Lisdexamfetamine is combined with Ketanserin.]
[J02AB02, ketoconazole, The metabolism of Lisdexamfetamine can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of hypertension can be increased when Ketoprofen is combined with Lisdexamfetamine.]
[L04AA24, abatacept, The metabolism of Lisdexamfetamine can be increased when combined with Abatacept.]
[R06AX25, mizolastine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Mizolastine.]
[S01GX08, ketotifen, Lisdexamfetamine may decrease the sedative and stimulatory activities of Ketotifen.]
[C01CA22, arbutamine, The risk or severity of hypertension can be increased when Arbutamine is combined with Lisdexamfetamine.]
[N04BC09, rotigotine, The metabolism of Lisdexamfetamine can be decreased when combined with Rotigotine.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Tiaprofenic acid.]
[C07AG01, labetalol, The therapeutic efficacy of Labetalol can be decreased when used in combination with Lisdexamfetamine.]
[N04BB01, amantadine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Lisdexamfetamine.]
[C02AA05, deserpidine, Lisdexamfetamine may decrease the antihypertensive activities of Deserpidine.]
[N04BA01, levodopa, The risk or severity of serotonin syndrome can be increased when Levodopa is combined with Lisdexamfetamine.]
[S02DA01, lidocaine, The metabolism of Lisdexamfetamine can be decreased when combined with Lidocaine.]
[N06BA13, armodafinil, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Armodafinil.]
[N02CA07, lisuride, The risk or severity of serotonin syndrome can be increased when Lisuride is combined with Lisdexamfetamine.]
[N06AA07, lofepramine, The therapeutic efficacy of Lofepramine can be increased when used in combination with Lisdexamfetamine.]
[C10AA02, lovastatin, The metabolism of Lisdexamfetamine can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, Loxapine may decrease the stimulatory activities of Lisdexamfetamine.]
[L01EG01, temsirolimus, The metabolism of Lisdexamfetamine can be decreased when combined with Temsirolimus.]
[G04BX01, magnesium hydroxide, The serum concentration of Lisdexamfetamine can be increased when it is combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The serum concentration of Lisdexamfetamine can be increased when it is combined with Magnesium oxide.]
[N06AA21, maprotiline, Lisdexamfetamine may decrease the sedative and stimulatory activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of serotonin syndrome can be increased when Mazindol is combined with Lisdexamfetamine.]
[C02BB01, mecamylamine, Lisdexamfetamine may decrease the antihypertensive activities of Mecamylamine.]
[R06AE05, meclizine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Meclizine.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Meclofenamic acid is combined with Lisdexamfetamine.]
[N02AB02, meperidine, The therapeutic efficacy of Meperidine can be increased when used in combination with Lisdexamfetamine.]
[C01CA11, mephentermine, The risk or severity of serotonin syndrome can be increased when Lisdexamfetamine is combined with Mephentermine.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be decreased when combined with Lisdexamfetamine.]
[N03AA01, mephobarbital, The serum concentration of Methylphenobarbital can be decreased when it is combined with Lisdexamfetamine.]
[N02AX05, meptazinol, Lisdexamfetamine may increase the analgesic activities of Meptazinol.]
[N05AC03, mesoridazine, Mesoridazine may decrease the stimulatory activities of Lisdexamfetamine.]
[N05AX13, paliperidone, The therapeutic efficacy of Paliperidone can be decreased when used in combination with Lisdexamfetamine.]
[C01CA09, metaraminol, The risk or severity of hypertension can be increased when Metaraminol is combined with Lisdexamfetamine.]
[A04AA04, dolasetron, The risk or severity of serotonin syndrome can be increased when Dolasetron is combined with Lisdexamfetamine.]
[N07BC02, methadone, Lisdexamfetamine may increase the analgesic activities of Methadone.]
[N06BA03, methamphetamine, The risk or severity of serotonin syndrome can be increased when Lisdexamfetamine is combined with Metamfetamine.]
[A03AB07, methantheline, Lisdexamfetamine may decrease the sedative and stimulatory activities of Methantheline.]
[R06AC05, methapyrilene, Lisdexamfetamine may decrease the sedative and stimulatory activities of Methapyrilene.]
[S01EC05, methazolamide, Methazolamide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.]
[J01XX05, methenamine, The serum concentration of Lisdexamfetamine can be decreased when it is combined with Methenamine.]
[G02CB05, metergoline, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Lisdexamfetamine can be decreased when combined with Methimazole.]
[N05AA02, methotrimeprazine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of hypertension can be increased when Methoxamine is combined with Lisdexamfetamine.]
[N02BG09, methoxyflurane, The risk or severity of hypertension can be increased when Methoxyflurane is combined with Lisdexamfetamine.]
[C02AB01, methyldopa, Lisdexamfetamine may decrease the antihypertensive activities of Methyldopa.]
[V04CG05, methylene blue, Lisdexamfetamine may increase the serotonergic activities of Methylene blue.]
[G02AB01, methylergonovine, The risk or severity of hypertension can be increased when Methylergometrine is combined with Lisdexamfetamine.]
[R03DA05, aminophylline, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Aminophylline.]
[N06BA04, methylphenidate, The risk or severity of hypertension can be increased when Methylphenidate is combined with Lisdexamfetamine.]
[N02CA04, methysergide, The risk or severity of hypertension can be increased when Methysergide is combined with Lisdexamfetamine.]
[A03FA01, metoclopramide, The metabolism of Lisdexamfetamine can be decreased when combined with Metoclopramide.]
[C03BA08, metolazone, Lisdexamfetamine may decrease the antihypertensive activities of Metolazone.]
[C07AB02, metoprolol, The metabolism of Lisdexamfetamine can be decreased when combined with Metoprolol.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Lisdexamfetamine.]
[N06AX03, mianserin, Lisdexamfetamine may decrease the sedative and stimulatory activities of Mianserin.]
[S02AA13, miconazole, The metabolism of Lisdexamfetamine can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Aminophenazone.]
[C01CA17, midodrine, The risk or severity of hypertension can be increased when Midodrine is combined with Lisdexamfetamine.]
[G03XB01, mifepristone, The metabolism of Lisdexamfetamine can be decreased when combined with Mifepristone.]
[C09CA03, valsartan, Lisdexamfetamine may decrease the antihypertensive activities of Valsartan.]
[D11AX01, minoxidil, Lisdexamfetamine may decrease the antihypertensive activities of Minoxidil.]
[N05AE02, molindone, Molindone may decrease the stimulatory activities of Lisdexamfetamine.]
[C01BD01, amiodarone, The metabolism of Lisdexamfetamine can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Lisdexamfetamine.]
[N02AA01, morphine, Lisdexamfetamine may increase the analgesic activities of Morphine.]
[A04AA05, palonosetron, The risk or severity of serotonin syndrome can be increased when Palonosetron is combined with Lisdexamfetamine.]
[L04AB05, certolizumab pegol, The metabolism of Lisdexamfetamine can be increased when combined with Certolizumab pegol.]
[G04BA01, ammonium chloride, The serum concentration of Lisdexamfetamine can be decreased when it is combined with Ammonium chloride.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Lisdexamfetamine.]
[G04CA04, silodosin, The therapeutic efficacy of Silodosin can be decreased when used in combination with Lisdexamfetamine.]
[N06AA17, amoxapine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Amoxapine.]
[N03AB05, fosphenytoin, The therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Lisdexamfetamine.]
[C07AA12, nadolol, The therapeutic efficacy of Nadolol can be decreased when used in combination with Lisdexamfetamine.]
[N02AF02, nalbuphine, Lisdexamfetamine may increase the analgesic activities of Nalbuphine.]
[N07BB04, naltrexone, Lisdexamfetamine may increase the analgesic activities of Naltrexone.]
[L04AC03, anakinra, The metabolism of Lisdexamfetamine can be increased when combined with Anakinra.]
[S01GA01, naphazoline, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Naphazoline.]
[N06BA01, amphetamine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Lisdexamfetamine.]
[M02AA12, naproxen, The risk or severity of hypertension can be increased when Naproxen is combined with Lisdexamfetamine.]
[N06AX21, duloxetine, The metabolism of Lisdexamfetamine can be decreased when combined with Duloxetine.]
[N01AH06, remifentanil, Lisdexamfetamine may increase the analgesic activities of Remifentanil.]
[N05AX14, iloperidone, Lisdexamfetamine may decrease the sedative and stimulatory activities of Iloperidone.]
[N06AX23, desvenlafaxine, The risk or severity of serotonin syndrome can be increased when Lisdexamfetamine is combined with Desvenlafaxine.]
[C09CA07, telmisartan, Lisdexamfetamine may decrease the antihypertensive activities of Telmisartan.]
[C10AD02, niacin, The metabolism of Lisdexamfetamine can be decreased when combined with Niacin.]
[N06AF02, nialamide, Nialamide may increase the hypertensive activities of Lisdexamfetamine.]
[C08CA04, nicardipine, The metabolism of Lisdexamfetamine can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, The therapeutic efficacy of Nicergoline can be decreased when used in combination with Lisdexamfetamine.]
[N07BA01, nicotine, The risk or severity of Tachycardia can be increased when Nicotine is combined with Lisdexamfetamine.]
[C08CA05, nifedipine, The metabolism of Nifedipine can be decreased when combined with Lisdexamfetamine.]
[M02AA17, niflumic acid, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Niflumic acid.]
[C08CA06, nimodipine, Lisdexamfetamine may decrease the antihypertensive activities of Nimodipine.]
[C08CA07, nisoldipine, Lisdexamfetamine may decrease the antihypertensive activities of Nisoldipine.]
[C08CA08, nitrendipine, Lisdexamfetamine may decrease the antihypertensive activities of Nitrendipine.]
[C02DD01, nitroprusside, Lisdexamfetamine may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Nitrous oxide.]
[C01CA03, norepinephrine, The therapeutic efficacy of Lisdexamfetamine can be increased when used in combination with Norepinephrine.]
[C02KX01, bosentan, Lisdexamfetamine may decrease the antihypertensive activities of Bosentan.]
[N06AA10, nortriptyline, Lisdexamfetamine may decrease the sedative and stimulatory activities of Nortriptyline.]
[G02CA02, nylidrin, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Nylidrin.]
[L04AC04, rilonacept, The metabolism of Lisdexamfetamine can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Lisdexamfetamine can be decreased when combined with Omeprazole.]
[N06AA05, opipramol, The therapeutic efficacy of Opipramol can be increased when used in combination with Lisdexamfetamine.]
[N02AA02, opium, Lisdexamfetamine may increase the analgesic activities of Opium.]
[R03CB03, metaproterenol, The risk or severity of hypertension can be increased when Orciprenaline is combined with Lisdexamfetamine.]
[G04CA02, tamsulosin, The therapeutic efficacy of Tamsulosin can be decreased when used in combination with Lisdexamfetamine.]
[P02BA02, oxamniquine, The metabolism of Lisdexamfetamine can be decreased when combined with Oxamniquine.]
[C07AA02, oxprenolol, The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Lisdexamfetamine.]
[N02AA05, oxycodone, Lisdexamfetamine may increase the analgesic activities of Oxycodone.]
[C01DX03, oxyfedrine, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of hypertension can be increased when Oxymetazoline is combined with Lisdexamfetamine.]
[N02AA11, oxymorphone, Lisdexamfetamine may increase the analgesic activities of Oxymorphone.]
[N05AE01, oxypertine, Oxypertine may decrease the stimulatory activities of Lisdexamfetamine.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, The risk or severity of Tachycardia can be increased when Oxyphenonium is combined with Lisdexamfetamine.]
[N05AH05, asenapine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Asenapine.]
[N02AX06, tapentadol, Lisdexamfetamine may increase the analgesic activities of Tapentadol.]
[M03AC01, pancuronium, The risk or severity of Tachycardia can be increased when Lisdexamfetamine is combined with Pancuronium.]
[C02KC01, pargyline, Pargyline may increase the hypertensive activities of Lisdexamfetamine.]
[G04BD11, fesoterodine, The metabolism of Fesoterodine can be decreased when combined with Lisdexamfetamine.]
[C07AA23, penbutolol, The therapeutic efficacy of Penbutolol can be decreased when used in combination with Lisdexamfetamine.]
[N05AG03, penfluridol, Penfluridol may decrease the stimulatory activities of Lisdexamfetamine.]
[N02AD01, pentazocine, Lisdexamfetamine may increase the analgesic activities of Pentazocine.]
[C04AD03, pentoxifylline, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Pentoxifylline.]
[N05AB10, perazine, Perazine may decrease the stimulatory activities of Lisdexamfetamine.]
[N04BC02, pergolide, The risk or severity of serotonin syndrome can be increased when Pergolide is combined with Lisdexamfetamine.]
[C08EX02, perhexiline, The metabolism of Lisdexamfetamine can be decreased when combined with Perhexiline.]
[N05AB03, perphenazine, Perphenazine may decrease the stimulatory activities of Lisdexamfetamine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Lisdexamfetamine.]
[N02AD02, phenazocine, Lisdexamfetamine may increase the analgesic activities of Phenazocine.]
[N06AF03, phenelzine, Phenelzine may increase the hypertensive activities of Lisdexamfetamine.]
[A10BA01, phenformin, The metabolism of Phenformin can be decreased when combined with Lisdexamfetamine.]
[R06AB05, pheniramine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Pheniramine.]
[N03AA02, phenobarbital, The serum concentration of Phenobarbital can be decreased when it is combined with Lisdexamfetamine.]
[N01AH04, phenoperidine, Lisdexamfetamine may increase the analgesic activities of Phenoperidine.]
[C04AX02, phenoxybenzamine, The therapeutic efficacy of Phenoxybenzamine can be decreased when used in combination with Lisdexamfetamine.]
[A08AA01, phentermine, The risk or severity of serotonin syndrome can be increased when Phentermine is combined with Lisdexamfetamine.]
[V03AB36, phentolamine, The therapeutic efficacy of Phentolamine can be decreased when used in combination with Lisdexamfetamine.]
[M02AA01, phenylbutazone, The risk or severity of hypertension can be increased when Phenylbutazone is combined with Lisdexamfetamine.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be increased when Phenylephrine is combined with Lisdexamfetamine.]
[R01BA01, phenylpropanolamine, The risk or severity of hypertension can be increased when Phenylpropanolamine is combined with Lisdexamfetamine.]
[N03AB02, phenytoin, The therapeutic efficacy of Phenytoin can be decreased when used in combination with Lisdexamfetamine.]
[L04AB06, golimumab, The metabolism of Lisdexamfetamine can be increased when combined with Golimumab.]
[C08CX01, mibefradil, The metabolism of Lisdexamfetamine can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, The therapeutic efficacy of Lisdexamfetamine can be decreased when used in combination with Pimozide.]
[C07AA03, pindolol, The therapeutic efficacy of Pindolol can be decreased when used in combination with Lisdexamfetamine.]
[J05AE01, saquinavir, The metabolism of Lisdexamfetamine can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Piperazine can be decreased when combined with Lisdexamfetamine.]
[N05AC04, pipothiazine, Pipotiazine may decrease the stimulatory activities of Lisdexamfetamine.]
[C09CA02, eprosartan, Lisdexamfetamine may decrease the antihypertensive activities of Eprosartan.]
[A02BX03, pirenzepine, The risk or severity of Tachycardia can be increased when Pirenzepine is combined with Lisdexamfetamine.]
[N02AC03, pirinitramide, Lisdexamfetamine may increase the analgesic activities of Piritramide.]
[S01BC06, piroxicam, The risk or severity of hypertension can be increased when Piroxicam is combined with Lisdexamfetamine.]
[N02CX01, pizotyline, Lisdexamfetamine may decrease the sedative and stimulatory activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Lisdexamfetamine can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, Lisdexamfetamine may decrease the antihypertensive activities of Irbesartan.]
[L04AC08, canakinumab, The metabolism of Lisdexamfetamine can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, Lisdexamfetamine may decrease the antihypertensive activities of Polythiazide.]
[J05AE03, ritonavir, The metabolism of Lisdexamfetamine can be decreased when combined with Ritonavir.]
[V03AB21, potassium iodide, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Potassium Iodide.]
[C07AB01, practolol, The therapeutic efficacy of Practolol can be decreased when used in combination with Lisdexamfetamine.]
[C02CA01, prazosin, The therapeutic efficacy of Prazosin can be decreased when used in combination with Lisdexamfetamine.]
[R06AX05, antazoline, Lisdexamfetamine may decrease the sedative and stimulatory activities of Antazoline.]
[P01BA03, primaquine, The metabolism of Lisdexamfetamine can be decreased when combined with Primaquine.]
[N03AA03, primidone, The serum concentration of Primidone can be decreased when it is combined with Lisdexamfetamine.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Lisdexamfetamine.]
[S01HA05, procaine, Procaine may increase the hypertensive activities of Lisdexamfetamine.]
[L01XB01, procarbazine, Procarbazine may increase the hypertensive activities of Lisdexamfetamine.]
[N05AB04, prochlorperazine, Prochlorperazine may decrease the stimulatory activities of Lisdexamfetamine.]
[N04AA04, procyclidine, The risk or severity of Tachycardia can be increased when Procyclidine is combined with Lisdexamfetamine.]
[G03DA04, progesterone, The metabolism of Progesterone can be decreased when combined with Lisdexamfetamine.]
[N05AA03, promazine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Promazine.]
[R06AD02, promethazine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Promethazine.]
[C01BC03, propafenone, The therapeutic efficacy of Propafenone can be decreased when used in combination with Lisdexamfetamine.]
[A03AB05, propantheline, The risk or severity of Tachycardia can be increased when Propantheline is combined with Lisdexamfetamine.]
[R06AX26, fexofenadine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Fexofenadine.]
[N05AC01, periciazine, The therapeutic efficacy of Periciazine can be decreased when used in combination with Lisdexamfetamine.]
[N05CM06, propiomazine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Propiomazine.]
[N01AX10, propofol, The risk or severity of hypertension can be increased when Propofol is combined with Lisdexamfetamine.]
[N02AC04, propoxyphene, Lisdexamfetamine may increase the analgesic activities of Dextropropoxyphene.]
[C07AA05, propranolol, The therapeutic efficacy of Propranolol can be decreased when used in combination with Lisdexamfetamine.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Propylthiouracil.]
[N02CC04, rizatriptan, The risk or severity of serotonin syndrome can be increased when Rizatriptan is combined with Lisdexamfetamine.]
[B01AC09, epoprostenol, Lisdexamfetamine may decrease the antihypertensive activities of Epoprostenol.]
[N06AA11, protriptyline, The therapeutic efficacy of Protriptyline can be increased when used in combination with Lisdexamfetamine.]
[R01BA02, pseudoephedrine, The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Lisdexamfetamine.]
[N05AX12, aripiprazole, Lisdexamfetamine may decrease the sedative and stimulatory activities of Aripiprazole.]
[A03AB15, diphemanil, The risk or severity of Tachycardia can be increased when Lisdexamfetamine is combined with Diphemanil.]
[A03AB09, isopropamide, The risk or severity of Tachycardia can be increased when Lisdexamfetamine is combined with Isopropamide.]
[S01FA03, methscopolamine, The risk or severity of Tachycardia can be increased when Lisdexamfetamine is combined with Methscopolamine.]
[R06AC01, pyrilamine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Mepyramine.]
[C01BA01, quinidine, The therapeutic efficacy of Quinidine can be decreased when used in combination with Lisdexamfetamine.]
[P01BC01, quinine, The metabolism of Lisdexamfetamine can be decreased when combined with Quinine.]
[A02BA02, ranitidine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Ranitidine.]
[C02AA01, rescinnamine, Lisdexamfetamine may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, The serum concentration of Lisdexamfetamine can be decreased when it is combined with Reserpine.]
[R03AC05, rimiterol, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of hypertension can be increased when Ritodrine is combined with Lisdexamfetamine.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hypertension can be increased when Sulfasalazine is combined with Lisdexamfetamine.]
[S01BC08, salicylic acid, The risk or severity of hypertension can be increased when Salicylic acid is combined with Lisdexamfetamine.]
[S01FA02, scopolamine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Lisdexamfetamine.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Selegiline.]
[C07AA07, sotalol, The therapeutic efficacy of Sotalol can be decreased when used in combination with Lisdexamfetamine.]
[R03BB01, ipratropium bromide, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Lisdexamfetamine.]
[N06AF04, tranylcypromine, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
[N06AF01, isocarboxazid, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
[N06AF03, phenelzine, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
[L01XB01, procarbazine, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
[N04BD01, selegiline, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
